Internet Archive Scholar

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients [article]

Rose-Marie Rebillard, Marc Charabati, Camille Grasmuck, Abdelali Filali-Mouhim, Olivier Tastet, Nathalie Brassard, Audrey Daigneault, Lyne Bourbonniere, Renaud Balthazard, Ana Carmena Moratalla, Yves Carpentier Solorio, Negar Farzam-kia (+15 others)
2020 medRxiv   pre-print

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.8 MB)
https://web.archive.org/web/20210428110604/https://www.medrxiv.org/content/medrxiv/early/2020/12/22/2020.12.21.20248642.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Dysregulated immune profiles have been described in symptomatic SARS-CoV-2-infected patients. Whether the reported immune alterations are specific to SARS-CoV-2 infection or also triggered by other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of i) patients hospitalized with acute SARS-CoV-2 infection; ii) patients of comparable age/sex hospitalized for other acute disease (SARS-CoV-2 negative); and iii) healthy
more » ... s. Using both data-driven and hypothesis-driven analyses, we found several dysregulations in immune cell subsets (e.g. decreased proportion of T cells) that are similarly associated with acute SARS-CoV-2 infection and non-COVID-19 related acute illnesses. In contrast, we identified specific differences in myeloid and lymphocyte subsets that are associated with SARS-CoV-2 status (e.g. elevated proportion of ICAM-1+ mature/activated neutrophils, ALCAM+ monocytes, and CD38+CD8+ T cells). A subset of SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days and mortality. Our data provides novel understanding of the immune dysregulation that are specifically associated with SARS-CoV-2 infection among acute care hospitalized patients. Our study lays the foundation for the development of specific biomarkers to stratify SARS-CoV-2+ patients at risk of unfavorable outcome and uncover novel candidate molecules to investigate from a therapeutic perspective.
doi:10.1101/2020.12.21.20248642 fatcat:ziwcqihrw5cjjpia6nukr7mtgi
Citation

Rose-Marie Rebillard, Marc Charabati, Camille Grasmuck, Abdelali Filali-Mouhim, Olivier Tastet, Nathalie Brassard, Audrey Daigneault, Lyne Bourbonniere, Renaud Balthazard, Ana Carmena Moratalla, Yves Carpentier Solorio, Negar Farzam-kia, Antoine Philippe Fournier, Elizabeth Gowing, Helene Jamann, Florent Lemaitre, Victoria Hannah Mamane, Karine Thai, Jean-Franois Cailhier, Nicolas Chomont, Andres Finzi, Michael Chasse, Madeleine Durand, Nathalie Arbour, Daniel E Kaufmann, Alexandre Prat, Catherine Larochelle. "Identification of SARS-CoV-2-specific immune alterations in acutely ill patients." medRxiv (2020)